ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3Genealiases: CENTD3 · DRAG1
Q-omics provides the consensus-scored ARAP3 profile across patient tissues and cancer cell-line models. ARAP3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ARAP3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, ARAP3 protein abundance shows 26,638 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where ARAP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARAP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARAP3 survival associations across molecular data types. ARAP3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARAP3 RNA expression–survival associations across cancer types. High ARAP3 expression shows unfavorable associations in KIRP, MESO, LGG and CESC, but favorable associations in UVM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ARAP3 RNA expression.
This table summarizes ARAP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARAP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARAP3 shows lower tumor expression in KIRP, LUSC, KICH and LUAD and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher ARAP3 RNA expression in tumor versus normal tissue (log2 FC = +1.278, t-test p < 0.001).
This table shows molecular features associated with ARAP3 in patient tissues and cancer cell lines. In patient samples, ARAP3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARAP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
